Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 16/20 | 0.60 |
| ▸ | TP53 | P04637 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | APAF1 | O14727 | 4/20 | 0.56 |
| ▸ | CASP3 | P42574 | 3/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | TDP2 | O95551 | 2/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4957199 | 0.81 | MAPT (0.61) | MAPTTP53ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4963803 | 0.77 | MAPT (0.67) | MAPTTP53ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4958725 | 0.77 | ADORA1 (0.60) | MAPTTP53ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4958817 | 0.76 | MAPT (0.52) | MAPTTP53ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4960364 | 0.76 | MAPT (0.73) | MAPTTP53ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4958411 | 0.75 | MAPT (0.57) | MAPTTP53ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4965626 | 0.75 | MAPT (0.59) | MAPTTP53ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4958350 | 0.72 | MAPT (0.68) | MAPTTP53ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1822988 | 0.71 | MAPT (0.70) | MAPTTP53ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4960241 | 0.68 | ADORA1 (0.61) | MAPTTP53ALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407977-B2 | Substituted N-acyl-2-aminothiazoles | HOFFMAN-LA ROCHE INC. (US) | 2008-08-05 | — | — | US | claimed |
| EP-1791822-A1 | SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-06 | — | — | EP | claimed |
| US-20060030589-A1 | Substituted N-acyl-2-aminothiazoles | HOFFMANN-LA ROCHE INC. | 2006-02-09 | — | — | US | claimed |
| WO-2006013054-A1 | SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | claimed |
| US-7407977-B2 | Substituted N-acyl-2-aminothiazoles | HOFFMAN-LA ROCHE INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1791822-A1 | SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| US-20060030589-A1 | Substituted N-acyl-2-aminothiazoles | HOFFMANN-LA ROCHE INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2006013054-A1 | SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030589-A1 | Substituted N-acyl-2-aminothiazoles | SLC5A2, ABAT, AGTR2 | MAPT 1360/4885TP53 4777/4885ALDH1A1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.